ClinicalTrials.gg
RecruitingNCT04104126Updated Jun 8, 2026

Blood Flow Restriction Therapy in Achilles Injury

An interventional study of Standard of Care Physical Therapy and Blood flow restriction in Achilles Injuries Tendon, sponsored by NYU Langone Health. Recruiting at 1 site in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-06-08.

Sponsored by NYU Langone Health · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Jun 2026, 5 months ago, but the record still lists the study as recruiting.
  • Started Oct 2021; still recruiting 5 years 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
57
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 23 studies in Tendon Injuries with a site in United States — 4 open to participants now, 7 under way, none of them phase 3. Tendon Injuries · United States.

Planned enrollment
6th of 18
57 · median 28
Started
2021
the only one that year
No phase
13 of 23
2 open now
Registered
15th of 23
by date

Among the 23 studies in Tendon Injuries with a site in United States, this one is the 6th largest by planned enrollment of the 18 interventional ones that give a count, is the only one that started in 2021, is one of 13 with no phase, and was the 15th registered.

Tendon Injuries

101 studies on the registry are indexed under Tendon Injuries; 28 are open to participants now.

Browse Tendon Injuries studies →

Open to participants now

4 of the 23 studies in Tendon Injuries with a site in United States are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 12 Tendon Injuries studies recruiting now, 5 (42%) set no upper age limit and 7 (58%) stop at 75 or younger; 3 take children under 18; 2 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies in Tendon Injuries with a site in United States, or all of them as a file.
02

Study summary

Blood flow restriction (BFR) therapy is a brief and partial restriction of venous outflow of an extremity during low load resistance exercises. It is a safe and effective method of improving strength in healthy and active individuals, recovering from orthopedic pathologies and procedures. This prospective, randomized study will look at the implications this form of treatment has on the rehabilitation of Achilles injuries.

03

Conditions studied

  • Achilles Injuries Tendon

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosed with Achilles Injury
  • Must be at least 18 years of age and younger than 65 years of age
  • Intention to receive physical therapy as standard of care

Exclusion criteria

Exclusion Criteria:

  • Patients with intention to receive standard therapy and not the study therapy
  • Patients with impaired circulation, peripheral vascular compromise, previous revascularization of the extremity, or severe hypertension
  • Younger than 18 years of age or older than 65
  • Legally incompetent or mentally impaired (e.g. minors, Alzheimer's subjects, dementia, etc.)
  • Any patient considered a vulnerable subject
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
57 participants (estimated)

Study arms

  • Active comparator
    Standard of Care Physical Therapy

    Patients with Achilles injury are prescribed PT for their treatment, therefore physical therapy is a standard of care treatment for patients with tendon pathology.

    Other: Standard of Care Physical Therapy

  • Experimental
    Blood flow restriction (BFR) therapy

    Blood flow restriction therapy is a blood pressure cuff placed around the desired limb with a handheld device that controls the pressure exerted by the cuff.

    Other: Blood flow restriction

Interventions

  • OtherStandard of Care Physical Therapy

    Will receive standard of care physical therapy

  • OtherBlood flow restriction

    Blood flow restriction therapy is a blood pressure cuff placed around the desired limb with a handheld device that controls the pressure exerted by the cuff. The cuff is placed around the desired limb before a specific exercise, the physical therapist determines the appropriate pressure and time, and the patient completes the exercise as they normally would. The monitor determines the limb occlusion pressure and has an automatic timer that will deflate after the specified time has elapsed.

06

What researchers measure

Primary outcomes

  1. efficacy of blood flow restriction therapy on patients with Achilles injury by measure pre and post blood flow restriction therapy measured by muscle strength

    Measure in increase of strength in the affected leg measured by Biodex.

    Time frame: 12 Months

  2. Measure of pain using Visual Analog Scale (VAS)

    Respondent selects a whole number (0-10 integers) that best reflects the intensity of their pain. For pain intensity, the scale is most commonly anchored by "no pain" (score of 0) and "pain as bad as it could be" or "worst imaginable pain" (score of 100 \[100-mm scale\])

    Time frame: 12 Months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Individual participant data that underlie the results reported in this article, after deidentification (text, tables, figures, and appendices).

Supporting information: Study protocol, Statistical analysis plan

Time frame: Beginning 9 months and ending 36 months following article publication or as required by a condition of awards and agreements supporting the research.

Access criteria: Requests should be directed to David.Bloom@nyulangone.org. To gain access, data requestors will need to sign a data access agreement.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2021 (actual). Primary completion is estimated for Jun 2026, 55 months after the start.

Of 37 non-industry interventional studies with no phase under Tendon Injuries, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 46. This study's planned 55 months is above that.

Counting every sponsor, half of 39 studies reached it within 14 months; a quarter within 7 and three quarters within 46.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 24, 2019
First posted
Sep 26, 2019
StartActual
Oct 8, 2021
Primary completionEst.
Jun 1, 2026
CompletionEst.
Jun 1, 2026
Last update
Jun 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04104126
Lead sponsor
NYU Langone Health
Responsible party
Sponsor
First posted
Sep 26, 2019
Start date
Oct 8, 2021
Primary completion
Jun 1, 2026 (estimated)
Completion
Jun 1, 2026 (estimated)
Last update
Jun 8, 2026

Study contacts

Larry Chen
Contact
Larry.Chen@nyulangone.org
(317)847-1784
Michael Moore
Contact
michael.moore@nyulangone.org
347-554-0183
Guillem Gonzalez-Lomas, MD
principal investigator · New York Langone Health

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion